Risperdal Consta for Bipolar Disorder

This study has been completed.
Sponsor:
Collaborator:
Janssen Pharmaceuticals
Information provided by (Responsible Party):
K.N. Roy Chengappa, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00177164
First received: September 12, 2005
Last updated: January 11, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2009
  Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Publications:
Chengappa KN Roy, Turkin SR, Schlicht P, Murphy S, Brar J, Fagiolini A, Houck PR, Garbut RG, Fredrick N. A Pilot, 15-month, Randomised Effectiveness Trial of Risperidone Long-Acting Injection (RLAI) Versus Oral Atypical Antipsychotic Agents (AAP) in Persons with Bipolar Disorder. Acta Neuropsychiatrica 22:68-80, 2010.